Completed PHASE3 INTERVENTIONAL NCT00002719

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Leukemia Neutropenia

Interventions amsacrine carmustine cytarabine etoposide filgrastim idarubicin mitoxantrone hydrochloride peripheral blood stem cell transplantation

Updated 5 times since 2017 Last updated: Jun 29, 2012 Started: Dec 31, 1995 Primary completion: Nov 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Leukemia and Neutropenia, this trial is completed. The trial is conducted by European Organisation for Research and Treatment of Cancer - EORTC and has accumulated 5 data snapshots since 1995. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC
Gruppo Italiano Malattie EMatologiche dell'Adulto

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy